Merck & Co Inc logo

Merck & Co Inc

MRK
Healthcare|Drug Manufacturers - General|USA
$120.85
+0.00 (+0.00%)
DCF (FCF)
$75.40
Tangible Book
$1.76
Graham Number
$18.83
Earnings Power
$41.17

Upcoming Data Readouts (45)

Jul 2026
Est. completion
P1Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
NCT04846920n=52
Aug 2026
Est. completion
P2Gastric Cancer
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer
NCT04745988n=43
Sep 2026
Est. completion
P1Non Small Cell Lung Cancer
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
NCT02998567n=60
Sep 2026
Est. completion
NAMultiple Sclerosis
Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis
NCT06068582n=270
Sep 2026
Est. completion
P1P2Lymphoma, B-Cell
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
NCT03162536n=190
Sep 2026
Est. completion
P2Ovarian Clear Cell Carcinoma
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
NCT05296512n=30
Sep 2026
Est. completion
P1Central Nervous System Tumors
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
NCT05081180n=17
Oct 2026
Est. completion
Early P1Parkinson's Disease (PD)
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
NCT07348250n=22
Oct 2026
Est. completion
P1Advanced Solid Tumor
Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908n=52
Oct 2026
Est. completion
P2Essential Thrombocythemia
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
NCT04262141n=4
Oct 2026
Est. completion
P2Cervix Cancer
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
NCT06266338n=30
Nov 2026
Est. completion
P1Acute Myeloid Leukemia
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05597306n=18
Dec 2026
Est. completion
P2Brain Metastases
Pembrolizumab In Central Nervous System Metastases
NCT02886585n=101
Dec 2026
Est. completion
P2Uveal Melanoma
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
NCT05524935n=37
Dec 2026
Est. completion
P1Lymphoma
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
NCT06475235n=15
Dec 2026
Est. completion
P1Multiple Myeloma in Relapse
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
NCT04184050n=100
Jan 2027
Est. completion
P2Metastatic Pancreatic Ductal Adenocarcinoma
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
NCT04666740n=63
Jan 2027
Est. completion
P2Cervical Intraepithelial Neoplasia
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
NCT04712851n=25
Feb 2027
Est. completion
P2Renal Cell Carcinoma (RCC)
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
NCT03634540n=118
Apr 2027
Est. completion
P2Anal Cancer
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
NCT06493019n=23

Awaiting Results (30)

Trials past primary completion date but still active — data readout may be imminent.

Jul 2026
P1
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT03932409
Jun 2026
P3
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295
Apr 2026
P2
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668
Apr 2026
P2
Cisplatin+Pembrolizumab+RT in Vulvar Cancer
NCT04430699
Mar 2026
P1
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
NCT03260491
Mar 2026
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
NCT06053749
Mar 2026
P2
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
NCT03401788
Mar 2026
P1
A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)
NCT06580587
Mar 2026
A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
NCT05421806
Dec 2025
P2
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT05558982

Recent Press Releases